Avis (CAR) shares have risen more than +20% over the last week as President Trump's 25% tariffs on all imported vehicles are likely to boost the fleet value for the leading rental car operator.
Shares of Avis Budget Group, Inc. have gained 20% recently due to President Trump's tariffs on new cars, which should benefit CAR's used car holdings. The 25% tariff on imported vehicles is expected to increase new car prices by 5-8%, driving up used car prices by 5-15%. Avis's financials are closely tied to used car prices, with potential gains of $3-4 billion from higher used car prices over the next 12-18 months.
On Thursday, stocks of car rental companies Hertz and Avis saw their values unexpectedly take off. As of midday, shares of Hertz Global Holdings were trading at around $4.15, an intraday increase of more than 20%.
Shares of Hertz (HTZ) and Avis Budget Group (CAR) surged on Thursday after US President Donald Trump announced a plan to impose a 25% tariff on imported vehicles. The proposed levies are expected to increase car prices, potentially driving more consumers toward rental services instead of purchasing new vehicles.
Geopolitical news is providing a lift to the auto rental sector.
Hertz Global Holding and Avis Budget Group shares surged after President Trump announced tariffs that would bring fresh complications to auto manufacturers.
Shares of highly shorted Hertz and Avis Budget Group surged on Thursday as U.S. President Donald Trump's plan to slap a 25% tariff on imported vehicles raised prospects of consumers opting for car rentals instead of buying expensive new cars.
Avis Budget (CAR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
The auto industry is currently in a state of nervous anticipation, and that's not good for associated companies. One striking case in point is auto rental mainstay Avis Budget Group (CAR -11.41%), whose share price according to data compiled by S&P Global Market Intelligence was down by more than 25% week to date as of early Friday morning.
Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval. AUTL has $657.1 million in cash, providing a cash runway of approximately 3 years, alleviating immediate financial concerns. The company faces significant competition in the CD19 CAR T-cell therapy market, making sales execution crucial for success.
Allogene Therapeutics: Disrupting CAR-T With A Scalable Model
Shares in Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) surged 13% in the first hour of trading after the company announced it had administered the first human dose of its experimental CAR-T cell therapy, HG-CT-1. The treatment is designed for adults with relapsed or treatment-resistant acute myeloid leukaemia, a condition with few options and a poor prognosis.